Safety and Immunogenicity of HPV16 E7/Algammulin.
Safety and Immunogenicity of HPV16 E7/Algammulinįrazer, I. 131-146) edited by Rafi Ahmed and Irvin S.Y. Vaccines for Human Papillomavirus Infection and Anogenital Disease. UK: The Parthenon Publishing Group Ltd.Ĭell mediated immunity to papillomavirusesĬell mediated immunity to papillomaviruses. Reproductive medicine in the twenty first century. Vaccines Against Human Papillomavirus Infection. Vaccines Against Human Papillomavirus Infectionīoslego, J., Liu, X. Washington, D.C.: Pan American Health Organisation. Vaccines: Preventing Disease & Protecting Health. 210-230) edited by Philippe Moingeon Stallergenes. Vaccines: Frontiers in Design and Development. (2005).ĭevelopment of a Vaccine Against Human Papillomavirus (HPV. doi: 10.1002/9781444312744.ch44ĭevelopment of a Vaccine Against Human Papillomavirus (HPVĮdwards, S. 609-621) edited by Jordan, J., Singer, A. Vaccines to prevent and treat human papillomavirus associated anogenital disease. Vaccines to prevent and treat human papillomavirus associated anogenital disease Vaccines against human papillomavirus infection. Vaccines against human papillomavirus infection Cambridge, United Kingdom: Cambridge University Press. New York, U.S.A.: Informa Healthcare.Īntigen recognition and self–non-self discriminationĪntigen recognition and self–non-self discrimination. Science Translational Medicine, 13 (612) eabd5524, eabd5524. and Sullivan, Mark (2021).ĭrug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Glenn, Ashton, Mark, Baell, Jonathan, Bettess, Michael, Brown, Michael P., Carter, Brett, Charman, William N., Davis, Christopher, Fisher, Simon, Frazer, Ian, Gautam, Anand, Jennings, Michael P., Kearney, Philip, Keeffe, Eloise, Kelly, Darren, Lopez, Angel F., McGuckin, Michael, Parker, Michael W., Rayner, Craig, Roberts, Brett, Rush, James S. Journal Article: Drug repurposing: Misconceptions, challenges, and opportunities for academic researchersīegley, C. (2021).Ī model of impaired Langerhans cell maturation associated with HPV induced epithelial hyperplasia. Tuong, Zewen K., Lukowski, Samuel W., Nguyen, Quan H., Chandra, Janin, Zhou, Chenhao, Gillinder, Kevin, Bashaw, Abate A., Ferdinand, John R., Stewart, Benjamin J., Teoh, Siok Min, Hanson, Sarah J., Devitt, Katharina, Clatworthy, Menna R., Powell, Joseph E. Journal Article: A model of impaired Langerhans cell maturation associated with HPV induced epithelial hyperplasia and Chandra, Janin (2021).Īcquisition of murine splenic myeloid cells for protein and gene expression profiling by advanced flow cytometry and CITE-seq. Rødahl, Inga, Gotley, James, Andersen, Stacey B., Yu, Meihua, Mehdi, Ahmed M., Christ, Angelika N., Hamilton-Williams, Emma E., Frazer, Ian H., Lukowski, Samuel W. Journal Article: Acquisition of murine splenic myeloid cells for protein and gene expression profiling by advanced flow cytometry and CITE-seq He was appointed Companion of the Order of Australia in the Queen’s Birthday Honours list in 2013. He was recipient of the Prime Ministers Prize for Science, and of the Balzan Prize, in 2008, and was elected Fellow of the Royal Society of London in 2012. He was recognised as Australian of the Year in 2006. He chairs the Australian Medical Research Advisory Board of the Medical Research Future Fund.
He was the inaugural president of the Australian Academy of Health and Medical Sciences, and a member of the Australian National Science and Technology Council. He heads a biotechnology company, Jingang Medicine (Aus) Pty Ltd, working on new vaccine technologies, and is a board member of several companies and not for profit organisations. He is recognised as co-inventor of the technology enabling the HPV vaccines, currently used worldwide to help prevent cervical cancer. As a professor at the University of Queensland, he leads a research group working at TRI in Brisbane, Australia on the immunobiology of epithelial cancers. Professor Ian Frazer is a clinician scientist, trained as a clinical immunologist in Scotland.